The last decade of microbicide clinical trials in Africa: From hypothesis to facts

AIDS

Volumn 24, Issue SUPPL. 4, 2010, Pages

  Ramjee, Gita ^a   Kamali, Anatoli ^b   McCormack, Sheena ^c  

^a SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^b MRC   (Uganda)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Africa; HIV; microbicide clinical trials; women

Indexed keywords

C 31G; CARBOPOL 974P; CARRAGEENAN; CELLULOSE SULFATE; COL 1492; MICROBICIDE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NONOXINOL 9; PRO 2000; SURFACTANT; UNCLASSIFIED DRUG;

AFRICA; CLINICAL ASSESSMENT; CLINICAL RESEARCH; DRUG EFFICACY; DRUG SAFETY; HEALTH PROGRAM; HEALTH PROMOTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PATIENT COUNSELING; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SOCIAL ASPECT;

ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, RECTAL; AFRICA SOUTH OF THE SAHARA; ANTI-INFECTIVE AGENTS; CLINICAL TRIALS AS TOPIC; FEMALE; HIV INFECTIONS; HIV-1; HUMANS;

EID: 78349289575     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/01.aids.0000390706.81383.f3     Document Type: Review

References (78)

1. CIOMS. International ethical guidelines for biomedical research involving human subjects. Geneva: The Council for International Organizations of Medical Sciences (CIOMS) in collaboration with the World Health Organization (WHO); 2002.
2. Wood K, Jewkes R. Violence, rape, and sexual coercion: everyday love in a South African township. Gend Dev 1997; 5:41-46.
3. Maharaj P. Patterns of condom use: perspectives of men in KwaZulu-Natal, South Africa. Dev South Afr 2005; 22:187-197.
4. Mantell J, Dworkin S, Exner T, Hoffman S, Smit J, Susser I. The promises and limitations of female-initiated methods of HIV/ STI protection. Soc Sci Med 2006; 63:1998-2009.
5. Van De Wijgert JHHM, Khumalo-Sakutukwa GN, Coggins C, Dube SE, Nyamapfeni P, Mwale M, et al. Men's attitudes toward vaginal microbicides and microbicide trials in Zimbabwe. Int Fam Plan Perspect 1999; 25:15-20.
6. Hladik F, Hope T. HIV infection of the genital mucosa in women. Curr HIV/AIDS Rep 2009; 6:20-28.
7. Stover J, Bertozzi S, Gutierrez J-P, Walker N, Stanecki KA, Greener R, et al. The global impact of scaling up HIV/AIDS prevention programs in low- and middle-income countries. Science 2006; 311:1474-1476.
8. US Food and Drug Administration. Investigational new drug application [21CFR312.21]; 2009. http://www.accessdata.fda.gov/ scripts/cdrh/cfdocs/cfcfr/ CFRSearch.cfm?fr=312.21 [Accessed 7 July 2010]
9. Stein ZA. HIV prevention: the need for methods women can use. Am J Public Health 1990; 80:460-462.
10. Cutler B, Justman J. Vaginal microbicides and the prevention of HIV transmission. Lancet Infect Dis 2008; 8:685-697.
11. Balzarini J, Van Damme L. Microbicide drug candidates to prevent HIV infection. Lancet 2007; 369:787-797.
12. Ndesendo V, Pillay V, Choonara Y, Buchmann E, Bayever D, Meyer L. A review of current intravaginal drug delivery approaches employed for the prophylaxis of HIV/AIDS and prevention of sexually transmitted infections. AAPS PharmSci-Tech 2008; 9:505-520.
13. Buckheit RW Jr, Watson KM, Morrow KM, Ham AS. Development of topical microbicides to prevent the sexual transmission of HIV. Antiviral Res 2010; 85:142-158.
14. Jennings R, Clegg A. The inhibitory effect of spermicidal agents on replication of HSV-2 and HIV-1 in-vitro. J Antimicrob Chemother 1993; 32:71-82.
15. Moench TR, Whaley KJ, Mandrell TD, Bishop BD, Witt CJ, Cone RA. The cat/feline immunodeficiency virus model for trans-mucosal transmission of AIDS: nonoxynol-9 contraceptive jelly blocks transmission by an infected cell inoculum. AIDS 1993; 7:797-802.
16. Polsky B, Baron P, Gold JM, Smith J, Jensen R, Armstrong D. In vitro inactivation of HIV-1 by contraceptive sponge containing nonoxynol-9. Lancet 1988; 331:1456-11456.
17. Krebs F, Miller S, Malamud D, Howett M, Wigdahl B. Inactiva-tion of human immunodeficiency virus type 1 by nonoxynol-9, C31G, or an alkyl sulfate, sodium dodecyl sulfate. Antiviral Res 1999; 43:157-173.
18. Protocol: Randomized Controlled Trial of SAVVY and HIV in Ghana. 2003. http://www.plosone.org/article/info:doi%2F10. 1371%2Fjournal.pone.0001474#pone. 0001474.s002 [Accessed 7 July 2010]
19. Simoes JA, Citron DM, Aroutcheva A, Anderson RA Jr, Chany CJ 2nd, Waller DP, et al. Two novel vaginal microbicides (polystyrene sulfonate and cellulose sulfate) inhibit Gardnerella vaginalis and anaerobes commonly associated with bacterial vaginosis. Antimicrob Agents Chemother 2002; 46:2692-2695.
20. Cheshenko N, Keller MJ, MasCasullo V, Jarvis GA, Cheng H, John M, et al. Candidate topical microbicides bind Herpes Simplex Virus glycoprotein B and prevent viral entry and cell-to-cell spread. Antimicrob Agents Chemother 2004; 48:2025-2036.
21. Pearce-Pratt R, Phillips D. Sulfated polysaccharides inhibit lymphocyte-to-epithelial transmission of human immunodeficiency virus-1. Biol Reprod 1996; 54:173-182.
22. Population Council. Carraguard Investigator's Brochure. 2005.
23. Ongradi J, Ceccherini-NelliL,PistelloM,SpecterS,Bendinelli M. Acid sensitivity of cell-free and cell-associated HIV-1: clinical implications. AIDS Res Hum Retroviruses 1990; 6:1433-1436.
24. O'Connor T, Kinchington D, Kangro H, Jeffries D. The activity of candidate virucidal agents, low pH and genital secretions against HIV-1 in vitro. Int J STD AIDS 1995; 6:267-272.
25. Rusconi S, Moonis M, Merrill DP, Pallai PV, Neidhardt EA, Singh SK, et al. Naphthalene sulfonate polymers with CD4-blocking and antihuman immunodeficiency virus type 1 activities. Antimicrob Agents Chemother 1996; 40:234-236.
26. Scordi-Bello I, Mosoian A, He C, Chen Y, Cheng Y, Jarvis G, et al. Candidate sulfonated and sulfated topical microbicides: comparison of antihuman immunodeficiency virus activities and mechanisms of action. Antimicrob Agents Chemother 2005; 49:3607-3615.
27. Miller C, Alexander N, Gettie A, Hendrickx A, Marx P. The effect of contraceptives containing nonoxynol-9 on the genital transmission of simian immunodeficiency virus in rhesus macaques. Fertil Steril 1992; 57:1126-1128.
28. Patton DL, Sweeney YTC, Balkus JE, Hillier SL. Vaginal and rectal topical microbicide development: safety and efficacy of 1.0% Savvy (C31G) in the pigtailed macaque. Sex Transm Dis 2006; 33:691-695.
29. Saifuddin M, Doncel G, Tsai L, Gettie A, Bhom R, Cheng-Mayer C. Intravaginal administration of 6% cellulose sulfate (CS) gel prevented systemic infection in rhesus macaques in a multiple dose R5/X4 SHIV vaginal challenge model. In: Microbicides 2008 Conference; Delhi, India; 24-27 February 2008.
30. Zeitlin L, Hoen T, Achilles S, Hegarty T, Jerse A, Kreider J, et al. Tests of Buffergel for contraception and prevention of sexually transmitted diseases in animal models. Sex Transm Dis 2001; 28:417-423.
31. Bourne N, Bernstein D, Ireland J, Sonderfan A, Profy A, Stan-berry L. The topical microbicide PRO 2000 protects against genital herpes infection in a mouse model. J Infect Dis 1999; 180:203-205. (Pubitemid 29293937)
32. Lewis M, Wagner W, Yalley-Ogunro J, Greenhouse J, Profy A. Efficacy of PRO 2000 gel in a macaque model for vaginal HIV transmission [abstract A-191]. In: Microbicides 2002; Antwerp, Belgium; 2002. http://www.itg.be/micro2002/ downloads/ abstracts.pdf [Accessed 7 July 2010]
33. Kreiss J, Ngugi E, Holmes K, Ndinya-Achola J, Waiyaki P, Roberts P, et al. Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA 1992; 268:477-482.
34. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002; 360:971-977.
35. Richardson BA, Lavreys L, Martin HL Jr, Stevens CE, Ngugi E, Mandaliya K, et al. Evaluation of a low-dose nonoxynol-9 gel for the prevention of sexually transmitted diseases: a randomized clinical trial. Sex Transm Dis 2001; 28:394-400.
36. Feldblum P, Adeiga A, Bakare R, Wevill S, Lendvay A, Obadaki F, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 2008; 3:e1471.
37. Peterson L, Nanda K, Opoku BK, Ampofo WK, Owusu-Amoako M, Boakye AY, et al. SAVVYW (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One 2007; 2:e1312.
38. Van Damme L, Govinden R, Mirembe F, Guédou F, Solomon S, Becker M, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008; 359:463-472.
39. Halpern V, Ogunsola F, Obunge O, Wang C-H, Onyejepu N, Oduyebo O, et al. Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS One 2008; 3:e3784.
40. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos M, Friedland B, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372:1977-1987.
41. Abdool Karim S, Coletti A, Richardson B, Ramjee G, Hoffman I, Chirenje M, et al. Safety and effectiveness of vaginal micro-bicides BufferGel and 0.5% PRO 2000 gel for the prevention of HIV infection in women: Results of the HPTN 035 trial [abstract 48LB]. In: 16th Conference on Retroviruses and Opportunistic Infections; Montréal, Canada; 8-11 February 2009.
42. MDP. Technical fact sheet for scientists. http://www.mdp. mrc.ac.uk/downloads/IS06%20-%20MDP%20Technical%20 Fact%20Sheet%20v1.2%20141209. pdf. [Accessed 9 April 2010]
43. Kilmarx PH, van de Wijgert JHHM, Chaikummao S, Jones HE, Limpakarnjanarat K, Friedland BA, et al. Safety and acceptability of the candidate microbicide Carraguard in Thai women: findings from a phase II clinical trial. J Acquir Immune Defic Syndr 2006; 43:327-334.
44. Coggins C, Blanchard K, Alvarez F, Brache V, Weisberg E, Kilmarx PH, et al. Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide. Sex Transm Infect 2000; 76:480-483.
45. Elias C, Coggins C, AlvarezF, Brache V, Fraser I, Lacarra M, et al. Colposcopic evaluation of a vaginal gel formulation of iota-carrageenan. Contraception 1997; 56:387-389.
46. Schwartz JL, Mauck C, Lai J-J, Creinin MD, Brache V, Ballagh SA, et al. Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind phase I safety study. Contraception 2006; 74:133-140.
47. Mauck C, Weiner DH, Ballagh S, Creinin M, Archer DF, Schwartz J, et al. Single and multiple exposure tolerance study of cellulose sulfate gel: a phase I safety and colposcopy study. Contraception 2001; 64:383-391.
48. Doh AS, Ngoh N, Roddy R, Lai J-J, Linton K, Mauck C. Safety and acceptability of 6% cellulose sulfate vaginal gel applied four times per day for 14 days. Contraception 2007; 76:245-249.
49. CONRAD. Phase III trials of cellulose sulfate microbicide for HIV prevention closed [press release]. 2007. http://www.medi calnewstoday.com/ articles/62310.php [Accessed 7 July 2010]
50. Family Health International (FHI). FHI closes phase III trial of cellulose sulfate for HIV prevention; Research Triangle Park, NC: FHI, January 31, 2007. http://www.fhi.org/en/AboutFHI/ Media/Releases/res-CS-Nigeria.htm. [Accessed 16 November 2009]
51. Nunn A, McCormack S, Crook A, Pool R, Rutterford C, Hayes R. Microbicides Development Programme: design of a phase III trial to measure the efficacy of the vaginal microbicide PRO 2000/5 for HIV prevention. Trials 2009; 10:99.
52. Olmsted S, Dubin N, Cone R, Moench T. The rate at which human sperm are immobilized and killed by mild acidity. Fertil Steril 2000; 73:687-693.
53. Mesquita PMM, Cheshenko N, Wilson SS, Mhatre M, Guzman E, Fakioglu E, et al. Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety. J Infect Dis 2009; 200:599-608.
54. Mâsse B, Boily M-C, Dimitrov D, Desai K. Efficacy dilution in randomized placebo-controlled vaginal microbicide trials. Emerg Themes Epidemiol 2009; 6:5.
55. Myer L, Kuhn L, Stein ZA, Wright JTC, Denny L. Intravaginal practices, bacterial vaginosis, and women's susceptibility to HIV infection: epidemiological evidence and biological mechanisms. Lancet Infect Dis 2005; 5:786-794.
56. Martin Hilber A, Chersich MF, van de Wijgert JHHM, Rees H, Temmerman M. Vaginal practices, microbicides and HIV: what do we need to know? Sex Transm Infect 2007; 83:505-508.
57. Hosegood V, McGrath N, Moultrie T. Dispensing with marriage: marital and partnership trends in rural KwaZulu-Natal, South Africa 2000-2006. Demogr Res 2009; 20:279-312.
58. Caldwell JC, Caldwell P. The cultural context of high fertility in sub-Saharan Africa. Popul Dev Rev 1987; 13:409-437.
59. Kunjara Na Ayudhya R, Hopkins N, Cost M, Billitto N, Rooney J, Dezzutti C. Microbicide, tenofovir 1% gel, efficacy determined for pre and postcoital use [abstract 1071]. In: 16th Conference on Retroviruses and Opportunistic Infections; Mon-tréal, Canada; 8-11 February 2009.
60. García-Lerma JG, Otten RA, Qari SH, Jackson E, Cong M-e, Masciotra S, et al Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricita-bine and tenofovir. PLoS Med 2008, 5 e28.
61. Denton PW, Estes JD, Sun Z, Othieno FA, Wei BL, Wege AK, et al. Antiretroviral preexposure prophylaxis prevents vaginal transmissionof HIV-1in humanized BLT mice. PLoS Med 2008; 5:e16.
62. Dobard C, Parikh U, Sharma S, Cong M-E, Smith J, Garcia-Lerma G, et al. Complete protection against repeated vaginal simian HIV exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine [abstract 46]. In: 16th Conference on Retroviruses and Opportunistic Infections; Mon-tréal, Canada; 8-11 February 2009.
63. Van Herrewege Y, Michiels J, Van Roey J, Fransen K, Kestens L, Balzarini J, et al. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob Agents Chemother 2004; 48:337-339.
64. Di Fabio S, Van Roey J, Giannini G, van den Mooter G, Spada M, Binelli A, et al. Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the nonnucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. AIDS 2003; 17:1597-1604.
65. Borkow G, Barnard J, Nguyen T, Belmonte A, Wainberg M, Parniak M. Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. J Virol 1997; 71:3023-3030.
66. Patton DL, Sweeney YTC, Balkus JE, Rohan LC, Moncla BJ, Parniak MA, et al. Preclinical safety assessments of UC781 antihuman immunodeficiency virus topical microbicide formulations. Antimicrob Agents Chemother 2007; 51:1608-1615.
67. Nel AM, Coplan P, van de Wijgert JH, Kapiga SH, von Mol-lendorf C, Geubbels E, et al. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS 2009; 23:1531-1538.
68. Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, Kwiecien A, et al. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS 2006; 20:543-551.
69. Schwartz JL, Kovalevsky G, Lai J-J, Ballagh SA, McCormick T, Douville K, et al. A randomized six-day safety study of an anti-retroviral microbicide candidate UC781, a nonnucleoside reverse transcriptase inhibitor. Sex Transm Dis 2008; 35:414-419.
70. Wilson DP, Coplan PM, Wainberg MA, Blower SM. The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics. Proc Natl Acad Sci \USA 2008; 105:9835-9840.
71. McGowan I. Rectal microbicides: a new focus for HIV prevention. Sex Transm Infect 2008; 84:413-417.
72. Patton DL, Sweeney YT, Paul KJ. A summary of preclinical topical microbicide rectal safety and efficacy evaluations in a pigtailed macaque model. Sex Transm Dis 2009; 36:350-356.
73. Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, Berry N, et al. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local preexposure application of tenofovir gel. PLoS Med 2008; 5:e157.
74. Ventuneac A, Carballo-Dieguez A, McGowan I, Dennis R, Adler A, Khanukhova E, et al. Acceptability of UC781 gel as a rectal microbicide among HIV-uninfected women and men. AIDS Behav 2010; 14:618-628.
75. Anton P, Adler A, Khanuknova E, Elliott J, Cumberland W, Zhou Y, et al. A Phase 1 rectal safety and acceptability study of UC781 microbicide gel [abstract 1066]. In: 16th Conference on Retroviruses and Opportunistic Infections; Montréal, Canada; 8-11 February 2009.
76. McGowan I. Microbicides for HIV prevention: reality or hope? Curr Opin Infect Dis 2010; 23:26-31.
77. CAPRISA. Microbicides. http://www.caprisa.org/Projects/ microbicides.html. [Accessed 6 November 2009]
78. Nel A, Smythe S, Young K, Malcolm K, McCoy C, Rosenberg Z, et al. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr 2009; 51:416-423.